Teclegiorgis Gebremariam1, Nathan P Wiederhold2, Abdullah Alqarihi1, Priya Uppuluri1,3, Nkechi Azie4, John E Edwards1,3, Ashraf S Ibrahim5,3. 1. Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA. 2. University of Texas Health Sciences at San Antonio, San Antonio, TX, USA. 3. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 4. Astellas Pharma, Northbrook, IL, USA. 5. Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA ibrahim@labiomed.org.
Abstract
OBJECTIVES: Previously we demonstrated the benefit of isavuconazole in treating murine mucormycosis due to Rhizopus. We wanted to determine the efficacy of isavuconazole in treating murine mucormycosis caused by Mucor, the second most common cause of the disease. Furthermore, because we previously determined that Rhizopus possesses the target enzyme for echinocandins and micafungin has activity against murine mucormycosis, we compared the activity of combination therapy (isavuconazole + micafungin) with placebo, either drug alone or standard therapy of liposomal amphotericin B (LAmB) in treating pulmonary murine mucormycosis caused by Rhizopus delemar. METHODS: In vitro susceptibility to isavuconazole of Mucorales was evaluated using the CLSI M38-A2 method. Immunosuppressed mice were intratracheally infected with either Mucor circinelloides or R. delemar. Treatment with isavuconazole (orally), micafungin (intraperitoneally), a combination of both or LAmB (intravenously) was compared, with survival and tissue fungal burden serving as primary and secondary endpoints, respectively. RESULTS: Isavuconazole was as effective as LAmB in prolonging survival of mice infected with M. circinelloides. Against R. delemar-induced mucormycosis, all monotherapy treatments significantly improved survival of mice versus placebo without showing superiority over one another. However, LAmB was superior in lowering fungal burden in target organs. Although combination therapy of isavuconazole + micafungin did not enhance survival of mice over monotherapy, antagonism was not detected between the two drugs. CONCLUSION: Isavuconazole is effective in treating pulmonary murine mucormycosis due to Mucor. In addition, combination therapy of isavuconazole + micafungin does not demonstrate synergy and it is not antagonistic against Rhizopus-induced mucormycosis.
OBJECTIVES: Previously we demonstrated the benefit of isavuconazole in treating murinemucormycosis due to Rhizopus. We wanted to determine the efficacy of isavuconazole in treating murinemucormycosis caused by Mucor, the second most common cause of the disease. Furthermore, because we previously determined that Rhizopus possesses the target enzyme for echinocandins and micafungin has activity against murinemucormycosis, we compared the activity of combination therapy (isavuconazole + micafungin) with placebo, either drug alone or standard therapy of liposomal amphotericin B (LAmB) in treating pulmonary murine mucormycosis caused by Rhizopus delemar. METHODS: In vitro susceptibility to isavuconazole of Mucorales was evaluated using the CLSI M38-A2 method. Immunosuppressed mice were intratracheally infected with either Mucor circinelloides or R. delemar. Treatment with isavuconazole (orally), micafungin (intraperitoneally), a combination of both or LAmB (intravenously) was compared, with survival and tissue fungal burden serving as primary and secondary endpoints, respectively. RESULTS:Isavuconazole was as effective as LAmB in prolonging survival of mice infected with M. circinelloides. Against R. delemar-induced mucormycosis, all monotherapy treatments significantly improved survival of mice versus placebo without showing superiority over one another. However, LAmB was superior in lowering fungal burden in target organs. Although combination therapy of isavuconazole + micafungin did not enhance survival of mice over monotherapy, antagonism was not detected between the two drugs. CONCLUSION:Isavuconazole is effective in treating pulmonary murine mucormycosis due to Mucor. In addition, combination therapy of isavuconazole + micafungin does not demonstrate synergy and it is not antagonistic against Rhizopus-induced mucormycosis.
Authors: P E Verweij; G M González; N P Wiedrhold; C Lass-Flörl; P Warn; M Heep; M A Ghannoum; J Guinea Journal: J Chemother Date: 2009-06 Impact factor: 1.714
Authors: Alexander J Lepak; Karen Marchillo; Jamie VanHecker; Daniel Diekema; David R Andes Journal: Antimicrob Agents Chemother Date: 2013-09-03 Impact factor: 5.191
Authors: Francisco M Marty; Luis Ostrosky-Zeichner; Oliver A Cornely; Kathleen M Mullane; John R Perfect; George R Thompson; George J Alangaden; Janice M Brown; David N Fredricks; Werner J Heinz; Raoul Herbrecht; Nikolai Klimko; Galina Klyasova; Johan A Maertens; Sameer R Melinkeri; Ilana Oren; Peter G Pappas; Zdeněk Ráčil; Galia Rahav; Rodrigo Santos; Stefan Schwartz; J Janne Vehreschild; Jo-Anne H Young; Ploenchan Chetchotisakd; Sutep Jaruratanasirikul; Souha S Kanj; Marc Engelhardt; Achim Kaufhold; Masanori Ito; Misun Lee; Carolyn Sasse; Rochelle M Maher; Bernhardt Zeiher; Maria J G T Vehreschild Journal: Lancet Infect Dis Date: 2016-03-09 Impact factor: 25.071
Authors: Ashraf S Ibrahim; Joel C Bowman; Valentina Avanessian; Keturah Brown; Brad Spellberg; John E Edwards; Cameron M Douglas Journal: Antimicrob Agents Chemother Date: 2005-02 Impact factor: 5.191
Authors: Shahid Husain; Barbara D Alexander; Patricia Munoz; Robin K Avery; Sally Houston; Timothy Pruett; Richard Jacobs; Edward A Dominguez; Jan G Tollemar; Katherine Baumgarten; Chen M Yu; Marilyn M Wagener; Peter Linden; Shimon Kusne; Nina Singh Journal: Clin Infect Dis Date: 2003-07-09 Impact factor: 9.079
Authors: Caitlin Reed; Richard Bryant; Ashraf S Ibrahim; John Edwards; Scott G Filler; Robert Goldberg; Brad Spellberg Journal: Clin Infect Dis Date: 2008-08-01 Impact factor: 9.079
Authors: Nathan P Wiederhold; Gennethel J Pennick; Sheryl A Dorsey; Wieslaw Furmaga; James S Lewis; Thomas F Patterson; Deanna A Sutton; Annette W Fothergill Journal: Antimicrob Agents Chemother Date: 2013-11-04 Impact factor: 5.191
Authors: C Martín de la Escalera; A I Aller; E López-Oviedo; A Romero; A I Martos; E Cantón; J Pemán; P García Martos; E Martín-Mazuelos Journal: J Antimicrob Chemother Date: 2008-03-07 Impact factor: 5.758
Authors: Teclegiorgis Gebremariam; Sondus Alkhazraji; Clara Baldin; Laura Kovanda; Nathan P Wiederhold; Ashraf S Ibrahim Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Trung Anh Trieu; María Isabel Navarro-Mendoza; Carlos Pérez-Arques; Marta Sanchis; Javier Capilla; Patricia Navarro-Rodriguez; Loida Lopez-Fernandez; Santiago Torres-Martínez; Victoriano Garre; Rosa María Ruiz-Vázquez; Francisco E Nicolás Journal: PLoS Pathog Date: 2017-01-20 Impact factor: 6.823
Authors: Matthew A Miller; Kyle C Molina; Jonathan A Gutman; Sias Scherger; Jessica M Lum; Sherif B Mossad; Mary Burgess; Matthew P Cheng; Sally T Chuang; Samantha E Jacobs; Dante P Melendez; Dimpy P Shah; Andrea Zimmer; M Rizwan Sohail; Sadia Syed; Randall C Walker; Eric M Poeschla; Maheen Z Abidi Journal: Open Forum Infect Dis Date: 2020-12-30 Impact factor: 3.835
Authors: Teclegiorgis Gebremariam; Sondus Alkhazraji; Abdullah Alqarihi; Nathan P Wiederhold; Laura K Najvar; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim Journal: J Fungi (Basel) Date: 2021-04-18
Authors: Teclegiorgis Gebremariam; Sondus Alkhazraji; Abdullah Alqarihi; Nathan P Wiederhold; Karen Joy Shaw; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191